ClinicalTrials.gg
RecruitingNCT05490862Updated Jun 6, 2023

Inflammatory Status of Monocytes in Obesity

An interventional study of Lifestyle Modification and Traditional Recommendations in Obesity and Cardiovascular Diseases, sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology. Recruiting at 1 site in Russian Federation. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2023, 3 years 2 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2022, registered Aug 2022).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Obesity with a site in Russian Federation — 3 open to participants now, 4 under way, none of them phase 3. Obesity · Russian Federation.

Planned enrollment
18th of 24
100 · median 220
Started
2022
with 3 others
No phase
9 of 33
2 open now
Registered
25th of 33
by date
Lead sponsor
3 of 33
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

Among the 33 studies in Obesity with a site in Russian Federation, this one is the 18th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 with no phase, and was the 25th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 33 studies in Obesity with a site in Russian Federation are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Obesity with a site in Russian Federation, or all of them as a file.
02

Study summary

The study of the pro-inflammatory activation of circulating monocytes/macrophages in obesity is the main problem of this project. The investigation of pro-inflammatory activation of monocytes and determination of the level of mitochondrial genome mutations, assessment of traditional CVD risk factors and the degree of cardiovascular risk and atherosclerosis indicators and their association will be investigated in dynamics on 12-weeks weight loss.

Read the detailed description

Obesity is one of the main risk factors for cardiovascular disease (CVD), which occupy the first place in the overall structure of mortality in developed countries, and therefore it is a serious medical and social problem and an urgent research topic in modern science. Inflammation is one of the key factors in the development of cardiovascular complications of obesity, in particular atherogenesis. Currently, the mechanisms of inflammation in obesity are widely studied, in experimental studies, special attention is paid to the study of macrophages of adipose tissue, their inflammatory activation and their role in the development of obesity-associated pathological conditions. Circulating monocytes in dense tissue differentiate into macrophages and play an important role in the pathogenesis of chronic inflammation. Increased pro-inflammatory activation of macrophages in the focus of inflammation can cause chronic inflammation and contribute to the development of atherosclerotic lesions in the vascular wall. Mitochondrial dysfunction may play a special role in the proinflammatory activation of monocytes since it leads to the accumulation of oxygen radicals and activates the excessive secretion of inflammatory mediators. Mitochondrial genome mutations are one of the possible mechanisms leading to the development of mitochondrial dysfunction. Previously, atherosclerosis-associated mutations of the mitochondrial genome were identified, however, in obesity, the level of mitochondrial heteroplasmy has not been studied. Weight loss is associated with a decrease in cardiovascular risk; however, the mechanisms of the cardioprotective effects of weight loss are not fully understood. The anti-inflammatory effects of vigorous exercise in obesity are being actively studied. The study of the pro-inflammatory activation of circulating monocytes/macrophages in obesity is the main problem of this project. The following tasks will be solved within the framework of the project: 1. Investigation of pro-inflammatory activation of monocytes and determination of the level of mitochondrial genome mutations in obese individuals. 2. Comprehensive assessment of the association of monocyte activation, mitochondrial genome mutations and traditional CVD risk factors and the degree of cardiovascular risk and atherosclerosis indicators in obese individuals. 3. Study on the effect of weight loss after a 3-month course of body weight loss, consisting of a set of physical exercises in combination with a low-calorie diet on the inflammatory status of monocytes in obese individuals.

As a result of the project, data on the inflammatory status of monocytes in obesity will be obtained and published, the effect of pro-inflammatory activation of monocytes, mitochondrial genome mutations in combination with traditional CVD risk factors on indicators of atherosclerosis and cardiovascular risk in obese individuals will be investigated. Data on the effect of a weight loss intervention (a combination of exercise complex and low-calorie diet) on the inflammatory status of monocytes will be obtained and published. The study of cellular markers of inflammation and the identification of mitochondrial genome mutations in obese individuals will deepen the understanding of the mechanisms of chronic inflammation in obesity and obesity-associated cardiovascular complications. The study of the effect of weight loss on the inflammatory status of monocytes - key cells in the development of chronic inflammation - may become a promising direction for the development of approaches for personalized pathogenetic therapy of obesity and prevention of obesity-associated cardiovascular complications.

03

Conditions studied

  • Obesity
  • Cardiovascular Diseases

Keywords

  • obesity
  • Cardiovascular risk factors
  • atherosclerosis
  • Inflammation
  • Monocytes
  • Cytokines
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Obese Weight Loss and Control groups Inclusion Criteria:

  • ≥30 kg/m2

Lean Control group Inclusion Criteria:

  • BMI \<25 kg/m2

Exclusion Criteria:

  • Diabetes Mellitus
  • Cancer
  • Uncontrolled Hypertension
  • Decompensated liver or kidney disease
  • III-IV classes of Chronic Heart Failure
  • Other chronic diseases (except CVDs) on permanent treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Obese Weight Loss group

    Low-calorie diet and regular physical trainings will be administered to obese participants (BMI \>30kg/m\^2).

    Behavioral: Lifestyle Modification

  • Active comparator
    Obese Control group

    Traditional weight loss recommendations will be provided to obese participants (BMI \>30kg/m\^2)

    Behavioral: Traditional Recommendations

  • No intervention
    Lean Control group

    The data of these subjects will be used as a control

Interventions

  • BehavioralLifestyle Modification

    An individualized low-calorie diet is characterized by sugars and starchy food intake restriction, 500 kcal daily energy deficit for 12 weeks (3 months). Regular physical activity is represented by individualized 30 minutes trainings on an anti-gravity treadmill 3 workouts per week for 12 weeks with individual targets of stepping activity, which will be evaluated according to personal fitness monitoring data

  • BehavioralTraditional Recommendations

    The list of traditional diet and physical activity recommendations for patients with obesity

06

What researchers measure

Primary outcomes

  1. Changes of pro-inflammatory macrophages activation

    The measurement of basal and lipopolysaccharide-induced tumor necrosis factor-α and interleukin-1β levels in the culture of cluster differentiation 14+ cells obtained from participants blood samples

    Time frame: Twice: Baseline, treatment week 12

  2. Mitochondrial genome mutations

    The assessment of mtDNA mutation heteroplasmy m.652delG, m.1555A\>G, m.3336T\>C, m.3256C\>T, m.5178C\>A, m.12315G\>A, m.13513G\>A, m.14459G\>A , m.14846G\>A и m.15059G\>A by real-time polymerase chain reaction

    Time frame: One time measurement (baseline)

Secondary outcomes

  1. Changes of body mass

    Includes repeated assessment of body mass (kg) and calculation of percentage of weight loss.

    Time frame: Twice: Baseline, treatment week 12

  2. Changes of body fat mass

    Includes repeated assessment of body fat mass (%) by bio-impedancemetry body composition analysis and calculation of fat mass loss.

    Time frame: Twice: Baseline, treatment week 12

  3. Changes of skeletal muscle mass

    Includes repeated assessment of skeletal muscle mass (%) by bio-impedancemetry body composition analysis and calculation of muscle mass changes (positivo or negative).

    Time frame: Twice: Baseline, treatment week 12

  4. Changes of Serum Cholesterol levels

    The measurement of serum total cholesterol and cholesterol sbgroups levels by standard laboratory procedures. The decrease of cholesterol levels is considereed as positeve effect.

    Time frame: Twice: Baseline, treatment week 12

  5. Framingham Risk Score

    The assessment of estimated 10-year cardiovascular risk (%) according to the Framingham Risk Score that varies from less than 10% (low risk) to more than 20% (high risk). The reduction od risk will be considered as positive effect of intervention.

    Time frame: Twice: Baseline, treatment week 12

  6. Intima-media thickness

    The assessment of intima-media thickness of common carotid artery evaluated by B-mode ultrasound imagining.

    Time frame: One time measurement (baseline)

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiovascular Pathology and Diet
    Moscow, 115446, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Per reasonable request to principal investigator

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 2 years after study completion

Access criteria: Per reasonable request

Data sharing details ↗ · www.ion.ru

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Sep 2023, 19 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 19 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2022
First posted
Aug 8, 2022
StartActual
Jan 11, 2022
Primary completionEst.
Sep 1, 2023
CompletionEst.
Dec 14, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05490862
Lead sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Collaborators
Petrovsky National Research Centre of Surgery
Responsible party
Yurgita R. Varaeva, MD, MRes (Dr, Research Fellow, Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology) — Principal investigator
First posted
Aug 8, 2022
Start date
Jan 11, 2022
Primary completion
Sep 1, 2023 (estimated)
Completion
Dec 14, 2023 (estimated)
Last update
Jun 6, 2023

Study contacts

Yurgita R Varaeva, MD, MRes
Contact
varaeva@ion.ru
+79253841894
Natalia Shaposhnikova, MD
Contact
buchkova@mail.ru
+7985 274 96 82
Yurgita R Varaeva, MD, MRes
principal investigator · Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion